SynthesisBMC cancer2026
Efficacy and safety of CD30-targeted chimeric antigen receptor T-cell therapy for lymphoma: a meta-analysis.
Synthesis in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical benefits of cluster of differentiation 30 (CD30)-target chimeric antigen receptor T-cell (CAR-T) therapy in patients with lymphoma remain controversial. This meta-analysis intended to comprehensively investigate the efficacy and safety of CD30-targeted CAR-T therapy in these patients.
methodsStudies on CD30-targeted CAR-T therapy for patients with lymphoma were searched comprehensively in Web of Science, PubMed, Embase, and Cochrane Library databases until March 2025. A single-arm meta-analysis was performed to calculate pooled proportions with 95% confidence intervals (CI). Heterogeneity was assessed using the I² statistic, and fixed- or random-effects models were applied accordingly. Efficacy and safety outcomes were extracted and analyzed.
resultsA total of seven studies containing 102 cases were included in this meta-analysis. The pooled rates (95% CI) of complete response, partial response, stable disease, and progressive disease were 43.5% (17.6%; 69.3%), 17.5% (3.0%; 31.9%), 17.8% (3.0%; 32.6%), 10.7% (4.8%; 16.6%), respectively. The pooled objective response rate (95% CI) and disease control rate (95% CI) were 66.1% (46.4%; 85.9%) and 89.3% (83.4%; 95.2%). Regarding safety results, the pooled incidences (95% CI) of cytokine release syndrome, nausea or vomiting, anemia, and thrombocytopenia were 57.7% (37.7%; 77.8%), 38.2% (11.3%; 65.1%), 79.1% (48.0%; 100.0%), and 70.2% (36.1%; 100.0%), respectively. No publication bias was observed in any outcome measures (all P > 0.05). Quality assessment showed that all included studies were of moderate-to-high quality. Moreover, sensitivity analyses exhibited high robustness of results.
conclusionCD30-targeted CAR-T therapy demonstrates promising objective response rates with manageable toxicities in patients with lymphoma. The findings of this meta-analysis provide preliminary descriptive evidence to inform future clinical research and exploratory application of CD30-targeted CAR-T therapy in lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.